Expression of IL-12A and EBI3 in Oral Squamous Cell Carcinoma and Their Effect on Immune Microenvironment

doi:10.13701/j.cnki.kqyxyj.2022.06.010

Abstract

Abstract: Objective: To investigate the expression of IL-35 subunits IL12A and EBI3 in oral squamous cell carcinoma(OSCC) and theirs relationship with clinicopathological features, prognosis, and immune microenvironment. Methods: The expression levels of IL-35 subunits IL-12A and EBI3, and neutrophil and CD4⁺T cell infiltration in normal and cancer tissues of 186 OSCC patients were detected by tissue microarray and immunohistochemistry. TCGA database and TIMER database were used to analyze the relationship between IL-12A and EBI3 and disease-free interval time and immune cell infiltration of OSCC. Results: The expression of IL-12A and EBI3 in tumor tissue was significantly higher than that in normal epithelium (P<0.001). The expression levels of IL-12A and EBI3 were correlated in tumor tissues (r=0.45, P<0.01). Kaplan-Meier survival analysis showed that patients with low expression of IL-12A and EBI3 had better prognosis (P<0.05) and longer disease-free interval time (P<0.05). IL-12A was associated with CD4⁺T infiltration (r=0.254, P<0.05). EBI3 was associated with neutropil infiltration(r=0.311, P<0.0001), respectively. Conclusion: The increased expression of IL-35 subunits IL-12A and EBI3 in OSCC can affect the prognosis of OSCC patients and the level of immune related cell infiltration.

Key words: IL-35, OSCC, prognosis, TME

LV Yinan, HU Yaying, ZHENG Xiaofeng, YANG Ke, ZHANG Jiali. Expression of IL-12A and EBI3 in Oral Squamous Cell Carcinoma and Their Effect on Immune Microenvironment[J]. Journal of Oral Science Research, 2022, 38(6): 533-539.

References

[1] 曹雨庵,郭伟.我国口腔鳞癌的治疗现状[J].实用肿瘤杂志,2012,27(2):109-112.
[2] 陈新,徐文健,周健,等.口腔鳞状细胞癌现状[J].口腔医学,2017,37(5):462-465.
[3] 胡雅英,陈文,张佳莉.IGF2BP2的异常表达影响OSCC的增殖和侵袭[J].口腔医学研究,2021,37(4): 354-359.
[4] Pylayeva-Gupta Y. Molecular pathways: Interleukin-35 in autoimmunity and cancer [J]. Clin Cancer Res, 2016, 22(20): 4973-4978.
[5] Huang C, Li N, Li Z, et al. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression [J]. Nat Commun, 2017, 8: 14035.
[6] Li T, Fan J, Wang B, et al. Timer: A web server for comprehensive analysis of tumor-infiltrating immune cells [J]. Cancer Res, 2017, 77(21): e108-e110.
[7] Weckx A, Riekert M, Grandoch A, et al. Time to recurrence and patient survival in recurrent oral squamous cell carcinoma [J]. Oral Oncol, 2019, 94: 8-13.
[8] Dourado MR, Korvala J, Åström P, et al. Extracellular vesicles derived from cancer-associated fibroblasts induce the migration and invasion of oral squamous cell carcinoma [J]. J Extracell Vesicles, 2019, 8(1): 1578525.
[9] Teymouri M, Pirro M, Fallarino F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases [J]. Int J Cancer, 2018, 143(9): 2105-2115.
[10] Tao Q, Pan Y, Wang Y, et al. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts [J]. Int J Cancer, 2015, 137(10): 2384-2393.
[11] Zhang T, Nie J, Liu X, et al. Correlation analysis among the level of IL-35, microvessel density, lymphatic vessel density, and prognosis in non-small cell lung cancer [J]. Clin Transl Sci, 2021, 14(1): 389-394.
[12] Nicholl MB, Ledgewood CL, Chen X, et al. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor [J]. Cytokine, 2014, 70(2): 126-133.
[13] Huang C, Li Z, Li N, et al. Interleukin 35 expression correlates with microvessel density in pancreatic ductal adenocarcinoma, recruits monocytes, and promotes growth and angiogenesis of xenograft tumors in mice [J]. Gastroenterology, 2018, 154(3): 675-688.
[14] Javvadi LR, Parachuru VPB, Milne TJ, et al. Expression of IL33 and IL35 in oral lichen planus [J]. Arch Dermatol Res, 2018, 310(5): 431-441.
[15] Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful [J]. Cancer Immunol Res, 2014, 2(2): 91-98.
[16] Hao S, Chen X, Wang F, et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells [J]. Carcinogenesis, 2018, 39(12): 1488-1496.
[17] Zou JM, Qin J, Li YC, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth [J]. Oncotarget, 2017, 8(20): 33501-33514.